Page last updated: 2024-10-28

hydroxychloroquine and Diabetic Ketoacidosis

hydroxychloroquine has been researched along with Diabetic Ketoacidosis in 2 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Diabetic Ketoacidosis: A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Chee, YJ1
Tan, SK1
Yeoh, E1
Croft, A1
Bucca, A1
Jansen, JH1
Motzkus, C1
Herbert, A1
Wang, A1
Hunter, BR1

Reviews

1 review available for hydroxychloroquine and Diabetic Ketoacidosis

ArticleYear
Dissecting the interaction between COVID-19 and diabetes mellitus.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-

2020

Other Studies

1 other study available for hydroxychloroquine and Diabetic Ketoacidosis

ArticleYear
First-time Diabetic Ketoacidosis in Type 2 Diabetics With Covid-19 Infection: A Novel Case Series.
    The Journal of emergency medicine, 2020, Volume: 59, Issue:5

    Topics: Anti-Bacterial Agents; COVID-19; Crystalloid Solutions; Diabetes Mellitus, Type 2; Diabetic Ketoacid

2020